Inside the Formula | They Named the Brand Because They Wanted to Be a Problem for the Supplement Industry

With Thorne & TESTED by SuppCo: Inside the Formula is a new sponsored series featuring brands in the TESTED by SuppCo certification program, where we spotlight the fascinating research behind products that have received the certification. Learn more about TESTED by SuppCo.

Forty years ago, someone looked at the supplement industry and decided the best way to fix it was to become a persistent, principled irritant, and then named their company accordingly.

The name was not an accident. 

Thorne was chosen because the founders wanted to be a thorn in the side of an industry that had grown comfortable with low-quality ingredients, unnecessary fillers, and the assumption that consumers would never dig deep enough to notice. The founding conviction was built around healthcare practitioners, doctors and clinicians who needed to recommend supplements to patients and could not afford to guess at whether a product would deliver what the label claimed. That practitioner-first standard demanded a level of rigor the rest of the category was not bothering with, and Thorne was founded to make that gap uncomfortable.

Four decades later, the brand has grown to serve seven million customers, including elite professional athletes, people managing chronic conditions, and everyday consumers trying to get the basics right. The name still fits. Rather than softening as the company scaled, the quality infrastructure got more elaborate. Where most supplement brands source commodity ingredients from whoever offers the best price, Thorne operates a preferred supplier network built around what are called "branded ingredients," materials that carry a proprietary name specifically because the manufacturer behind them has invested in clinical research and standardized the active compound content. If you can name the ingredient, you can verify the science. If you cannot name it, you cannot.

The science question is where Thorne's process gets genuinely unusual for a supplement company. Brian Shira, Senior Director of Quality Control, describes a system where Thorne's medical affairs group uses clinical evidence as a hard gating criterion for formulation, not a nice-to-have, but a requirement. If a branded ingredient lacks relevant clinical trials, the team goes looking for a different ingredient. 

That standard recently forced a complete reformulation of a new product because the available clinical data had been generated in men and assumed to apply to women. Medical affairs pushed back, demanded studies in female subjects, and the women's libido support product that came out of that process is formulated with multiple botanicals specifically because each one had clinical support in women. That is the kind of decision that costs time and money and does not make it onto the label.

SuppCo anonymously purchased a wide range of Thorne products the same way any consumer would. No advance notice, no special batches. Just standard orders placed and shipped. An independent laboratory tested those products for active ingredient accuracy across the lineup.

While all products passed, two results are worth highlighting: Thorne's Creatine and Magnesium Bisglycinate delivered on their label claims, with active ingredient levels confirmed at stated amounts. For a brand that stakes its reputation on using chelated mineral forms and specific compound grades rather than cheaper commodity alternatives, that distinction matters. A magnesium bisglycinate that actually contains magnesium oxide is a different product biologically. Independent testing across a broad product portfolio is how a consumer knows which one they actually received.

I sat down with Brian Shira, Senior Director of Quality Control at Thorne, to dive deeper into the science.

JG: "Most supplement brands talk about quality. What does that word actually mean operationally at Thorne?"

BS: "Quality is adherence to a standard. That standard has transparency and efficacy built into it. With sourcing, it means we aren't buying commodity ingredients. We've identified branded suppliers, partnered with them, and built a rigorous test program with our medical affairs group to define exactly what we want to see, whether that's a specific active compound at a specific level or the complete absence of contaminants. All of those are important to build trust and deliver a quality product."

JG: "You test every incoming lot of raw material. Most brands use skip lot testing instead. Why does that difference matter?"

BS: "Skip lot testing is largely a cost-saving measure. The challenge is you can be blind. If a lot slips through your incoming inspection, you're adding manufacturing value to that material the whole way through, mixing it, encapsulating it, getting it to finished product stage, and then you might be surprised when you go to verify it at the end. We prefer to catch it at the door. You're going to pay now or pay later. We just prefer upfront."

JG: "What actually happens inside Thorne when something fails testing?"

BS: "If an out-of-specification result is confirmed, it goes to a material review board, a cross-functional group that can include medical affairs, quality control, and production. They review the confirmed result and determine the outcome: rework, retest, or outright rejection. We modeled this on the pharmaceutical industry. And we keep our QC compliance group structurally separate from the lab that ran the original test, specifically to remove any conflict of interest from that review. If it's a vendor material, we'll work with them to find replacement material, understand what went wrong, and make sure it doesn't happen again."

JG: "Why pursue an external certification when you already have internal testing this rigorous?"

BS: "It lets us hold up a mirror. Richard Feynman said it best: 'The first principle is that you must not fool yourself, and you are the easiest person to fool.' We want partners who help us make sure we aren't. The SuppCo certification lets us evaluate our quality from a different viewpoint, ask where we did things really well, and ask where we had assumptions we didn't even know we were making. Sometimes you need an outside check to find the things your internal process has stopped questioning."

A Thorn That Kept Its Edge

I approach quality narratives in the supplement industry with a fair amount of skepticism. After years in supplement science, I have watched many brands perform quality, the certifications, the manufacturing language, the clinical buzzwords, while the systems underneath those claims are largely theoretical. A well-written quality manual and an actual quality culture are two different things.

What stands out about Thorne is the specificity. Not "we test our products" but every incoming lot of every raw material, with a pharmaceutical-modeled material review board and a compliance team kept structurally independent from the lab that generated the original result. That structural separation is a real design choice. 

A quality control lab that also decides what to do when its own results fail has an obvious incentive to find reasons those results were wrong.

Thorne removed that temptation by keeping a separate compliance group, structurally independent from the lab, in charge of any out-of-specification investigation.

The detail that stayed with me most was the women's libido product story. Walking away from an ingredient mid-formulation because the clinical evidence was built in men and assumed to apply to women is not the kind of decision a brand makes to hit a launch window. It is the kind of decision a brand makes when the internal pressure to defend claims is real and non-negotiable. The broader supplement industry's problem with male-default clinical evidence is a genuine scientific issue. That Thorne's medical affairs team raised it in a product meeting, and that it changed the formulation, is a small but specific signal about what the culture actually values.

What I cannot fully evaluate from a single conversation is whether these systems hold consistently at scale across a large product portfolio. Rigorous processes can drift as companies grow. What I can say is that the architecture Shira described is more honest about its own failure modes than most, and the TESTED by SuppCo results provided the external data point to verify those label claims independently on two of their core products.

There is something worth noting about a quality director who cites Feynman unprompted to explain why his brand invited outside scrutiny. Most supplement brands do not want to be checked. Thorne named themselves after the idea of making that discomfort impossible to ignore.